Table 4 Overview of Psychometric Articles Identified
From: Health-related quality of life in women with breast cancer: a review of measures
Reference | Primary Instrument | Objective | Population | Sample Size and Age |
|---|---|---|---|---|
EORTC | ||||
Alawadhi et al. [10] | EORTC QLQ-BR23/EORTC QLQ-C30 | ▪ Assess the psychometric characteristics of both questionnaires using the responses of a larger sample of Arab women | ▪ Women attending follow-up clinic appointment for chemotherapy | ▪ 348 women ▪ Mean (SD) age: 48.3 (10.3) y |
Bener et al. [11] | EORTC QLQ-C30 | ▪ Assess psychometric properties of the Arabic version for patients in Qatar with breast cancer | ▪ Patients with breast cancer identified from hospital-based disease registry (ICD-10 code C50) | ▪ 678 patients with breast cancer ▪ Mean (SD) age: 47.7 (10.2) y |
Bjelic-Radisic et al. [12] | EORTC QLQ-BR23/QLQ-BR45 | ▪ Phase I-III study updating the EORTC QLQ-BR23 | ▪ Patient data that were included in an extensive literature systematic review to identify relevant QoL issues; interviews with patients and health care providers | ▪ 250 patients from 12 countries |
Cerezo et al. [13] | EORTC QLQ-BR23 | ▪ Validate the Mexican-Spanish version EORTC QLQ-BR23 | ▪ Women with biopsy-proven breast carcinoma | ▪ 234 women were included ▪ Mean (SD) age: 52.9 (11.8) y |
El Fakir et al. [14] | EORTC QLQ-BR23 | ▪ Test the reliability and validity of the Moroccan Arabic version | ▪ Subjects were eligible if they were aged at least 18 y, had a confirmed diagnosis of breast cancer, and spoke Moroccan Arabic | ▪ 105 patients participated (37 for test-retest) ▪ Mean age: 48 y |
Keilmann et al. [15] | EORTC QLQ-C30 | ▪ Investigate the reliability of a German, tablet-based version of the EORTC QLQ-C30 | ▪ Female patients with breast cancer in adjuvant and metastatic situation | ▪ 106 patients |
Michels et al. [16] | EORTC QLQ-BR23/EORTC QLQ-C30 | ▪ To validate and assess reliability and understanding of the EORTC QLQ-C30 and the EORTC QLQ-BR23 (in Brazil) | ▪ Women aged between 27 and 90 y, diagnosed with breast cancer, treated or in treatment, at any disease stage | ▪ 100 women ▪ Mean (SD) age: 56.5 (12.4) y |
Shuleta- Qehaja et al. [17] | EORTC QLQ-C30 | ▪ Evaluate the validity and reliability of the QLQ-C30 in Albanian women with breast cancer | ▪ Sample of patients with breast cancer | ▪ 62 women ▪ Mean (SD) age: 50 (10.9) y |
Simons [18] | EORTC QLQ-C30 | ▪ Assess content validity for signs and symptoms component | ▪ Women with locally advanced or metastatic breast cancer were required to have received prior treatment with an anthracycline, a taxane, and capecitabine | ▪ 283 women provided 1068 questionnaires ▪ Age- NR |
Snyder et al. [19] | EORTC QLQ-C30 | ▪ Test the replicability of the QLQ-C30 cutoff scores from previous study | ▪ Inclusion criteria: diagnosis of breast cancer, age at least 20 y, awareness of cancer diagnosis, and Eastern Cooperative Oncology Group (ECOG) performance status of 0–3 | ▪ 408 Japanese ambulatory patients with breast cancer ▪ Mean age: 56 y |
Tan et al. [20] | EORTC QLQ-BR23/EORTC QLQ-C30 | ▪ Validate EORTC QLQ-C30 and EORTC QLQ-BR23 questionnaires ▪ Measure HRQoL of women with breast cancer in Singapore during their first 4 y of postdiagnosis and treatments | ▪ Women older than 21 y with breast cancer stage 0 to 3A and in the first 4 y of postinterventions were recruited | ▪ 170 patients participated in the study ▪ Mean ± SD age: 54 ± 9 y |
Wallwiener et al. [21] | EORTC QLQ-C30 and FACT-B | ▪ Analyze acceptance of an electronic patient-reported outcome survey tool in patients with breast cancer | ▪ Patients with breast cancer in adjuvant and metastatic situation | ▪ 110 patients ▪ Mean age: 52.4 y |
Wallwiener et al. [22] | EORTC QLQ-C30 | ▪ Analyze the reliability of a tablet-based measuring application for EORTC QLQ-C30 in German | ▪ Female patients with adjuvant and metastatic breast cancer | ▪ 106 women ▪ Arm A (n = 53) completed tablet, then paper version ▪ Arm B (n = 53) completed paper, then tablet version ▪ Age: NR |
Zhang et al. [23] | EORTC QLQ-BR23 | ▪ Evaluate the reliability and validity of the Chinese version | ▪ Patients were included if they were aged > 18 y and had histological conformation of breast cancer | ▪ 294 outpatients with breast cancer ▪ Mean age: 53.1 y |
FACT-B | ||||
Algamdi and Hanneman [24] | FACT-B | ▪ Test reliability of the Arabic version of the FACT-B in women with breast cancer | ▪ Community-dwelling adults (aged 18–75 y) Arabic-speaking persons diagnosed with cancer (patients with breast cancer completed the FACT-B) | ▪ 29 women with breast cancer ▪ Age - NR |
Cheung et al. [25] | FACT-B | ▪ Compare the measurement precision and related properties between EQ-5D-5L and FACT-B questionnaires in assessing breast cancer patients | ▪ Asian patients with breast cancer | ▪ Observational study of 269 Singaporean patients with breast cancer ▪ Age: NR |
Jarkovsky et al. [26] | FACT-B | ▪ Validate FACT-B translation to the Czech language | ▪ Consecutive patients with breast cancer | ▪ 106 patients with breast cancer; 83 selected for psychometric testing |
Kobeissi et al. [27] | FACT-B | ▪ Translate, adapt, and face-validate the FACT-B into Arabic, specifically in the context of the Lebanese culture | ▪ Lebanese females who met the following inclusion criteria: breast cancer diagnosis, patient follow-up by oncology clinics, patient awareness of their diagnosis, patient willingness to share their experiences | ▪ Face-to-face interviews with individual patients with breast cancer (n = 33) and 2 focus groups (4 women/group) ▪ Mean (SD) age: 47.2 (11.8) y |
Lee et al. [28] | FACT-B | ▪ Compare the measurement properties between the EQ-5D-5L and the FACT-B | ▪ Singaporean, histologically confirmed patients with breast cancer who were aged at least 21 y | ▪ 269 women ▪ Mean (SD) age: 52.1 (9.9) y |
Matties et al. [29] | FACT-B | ▪ Analyze the reliability of tablet-based measurement of FACT-B in the German language | ▪ Paper- and tablet-based questionnaires were completed by 106 female adjuvant and patients with metastatic breast cancer | ▪ Arm A (n = 53) completed tablet, then paper version ▪ Arm B (n = 53) completed paper, then tablet version ▪ Age- NR |
Ng et al. [30] | FACT-B | ▪ Examine the measurement properties of and comparability between the English and Chinese versions of the FACT-B in Singaporean patients with breast cancer | ▪ Histologically confirmed breast cancer, at least 21 y old, ability to understand Chinese or English or both | ▪ 271 patients in the analysis ▪ Mean (SD) age: English: 50.7 (9.7) y Chinese: 54.6 (9.8) y |
Patoo et al. [31] | FACT-B | ▪ Validate the FACT-B in a sample of Iranian women with breast cancer | ▪ Breast cancer diagnoses, outpatients or inpatients with a pathologic diagnosis of cancer with any type or stage | ▪ 300 women ▪ Mean age: 47.27 y |
FBSI | ||||
Lee et al. [32] | FBSI | ▪ Examine the measurement properties of and comparability between the English and the Chinese versions of the FBSI and to compare it with its parent instrument, the FACT-B, in Singaporean patients with breast cancer | ▪ Histologically confirmed breast cancer, at least 21 years old, ability to understand Chinese or English or both | ▪ 271 patients in the analysis ▪ Mean (SD) age: English: 50.7 (9.7) y Chinese: 54.6 (9.8) y |
NFBSI-16 | ||||
Garcia et al. [33] | NFBSI-16 | ▪ Develop a new version of the FBSI that is in accordance with the FDA guidance for patient-reported outcome measures, provide assessment on a symptom level, and improve upon the original FBSI by emphasizing the patient input | ▪ 18 y old and diagnosed with stage III or IV breast cancer. They must have had experience with chemotherapy for at least 2 cycles (or 1 month with noncyclical chemotherapy) | ▪ 52 patients with stage III or IV breast cancer ▪ Mean age: 54 y |
Krohe et al. [34] | NFBSI-16 | ▪ Evaluate content validity of the NFBSI-16 and the PROMIS Physical Function SF10b | ▪ Adult man or woman (≥18 y of age); clinician confirmation of metastatic or locally advanced breast cancer not amenable to curative treatment by surgery or radiotherapy; clinician confirmation of hormone-receptor positive (HR+; estrogen receptor positive and/or progesterone receptor positive) and human epidermal growth factor receptor-2–negative (HER2-) breast cancer | ▪ 15 cognitive debriefing interviews ▪ Mean (SD) age: 66.0 (12.4) |
YW-BCI36 | ||||
Christophe et al. [35] | Young Women with Breast Cancer Inventory | ▪ Validate, in a large sample of patients, a questionnaire specifically measuring the subjective experience of the disease and its treatment in young women (aged < 45 y when diagnosed) living with a nonmetastatic breast cancer and the repercussions of the disease and its treatment they perceive in their daily life | ▪ Aged < 45 y at their diagnosis for a nonmetastatic breast cancer, had received or were receiving chemotherapy | ▪ 546 patients ▪ Mean (SD) age: 40.64 (6.21) y |
Breast Cancer Symptom Scale | ||||
Horigan et al. [36] | Breast Cancer Symptom Scale | ▪ Determine issues important to patients with breast cancer | ▪ Web-based survey from patients included in the NexCura information resource | ▪ N = 1072 patients ▪ Median age: 53 y |
QLICP-BR | ||||
Wan et al. [37] | Quality of Life Instruments for Cancer Patients-Breast Cancer | ▪ Develop and validate a QoL instrument for patients with breast cancer in China | ▪ Breast cancer inpatients at any stages and treatments | ▪ Inpatients (N = 186) with breast cancer answered the questionnaires at the time of admission to the hospital. 166 were entered to participate in a second assessment the following day or the second day after hospitalization to evaluate test-retest reliability. 94 cases were sampled randomly and assessed a third time after treatment to evaluate responsiveness. ▪ Mean (SD) age: 48.5 (10.1) y |
QuEST-Br | ||||
Harley et al. [38] | QuEST-Br | ▪ Adapt previously existing HRQoL measures to generate a tool for use in routine clinical practice | ▪ Patients in this study were attending outpatient clinics for review or chemotherapy treatment for breast cancer | ▪ N = 145 patients with breast cancer ▪ Mean (SD): 51 (11.6) y |
INA-BCHRQoL | ||||
Saptaningsih et al. [39] | Indonesian Breast Cancer Health-Related Quality of Life | ▪ Develop a new questionnaire in order to capture not only patients’ physical, cognitive, and psychological aspects but also the spiritual aspect | ▪ Women with a diagnosis of breast cancer stage I to IIIA, confirmed by pathology and anatomy assessment or cytology test, who received surgery and combined with fluorouracil, doxorubicin, and cyclophosphamide (FAC)– or taxan-based chemotherapy | ▪ N = 24 patients ▪ Age: 83% ≥40 y |
Unnamed | ||||
Deshpande et al. [7] | Newly developed, unnamed measure | ▪ Develop and validate a patient-reported questionnaire to assess the QoL outcomes of Indian breast cancer patients | ▪ Patients with breast cancer irrespective staging of cancer and type of therapy | ▪ N = 30 patients ▪ Age: NR |
Vanlemmens et al. [9] | Newly developed, unnamed measure | ▪ Analyze the quality of life of young women (< 45 y) with nonmetastatic breast cancer and their partners, | ▪ Young patients (aged < 45 y at the time of diagnosis) with nonmetastatic breast cancer and living with a partner were targeted | ▪ N = 69 couples ▪ Age: NR |
Vanlemmens et al. [8] | Unnamed measure (same as in 2009 publication) | ▪ Create a particular and specific inventory for measuring the impact of breast cancer on the quality of life of young women (aged < 45 y) with nonmetastatic disease and the quality of life of their partners; this work presents the psychometric validation | ▪ Women aged < 45 y when diagnosed and treated or been treated by chemotherapy for a nonmetastatic breast cancer and partners | ▪ N = 546 patients and n = 499 partners ▪ Age: NR |